Head to Head Contrast: Gilead Sciences (NASDAQ:GILD) & Xenetic Biosciences (NASDAQ:XBIO)

Gilead Sciences (NASDAQ:GILD) and Xenetic Biosciences (NASDAQ:XBIO) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Profitability

This table compares Gilead Sciences and Xenetic Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Insider & Institutional Ownership

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Gilead Sciences has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Gilead Sciences and Xenetic Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0	6	23	0	2.79
Xenetic Biosciences	1	0	0	0	1.00

Gilead Sciences presently has a consensus price target of $162.00, indicating a potential downside of 5.66%. Given Gilead Sciences’ stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Xenetic Biosciences.

Valuation and Earnings

This table compares Gilead Sciences and Xenetic Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44 billion	7.23	$8.51 billion	($2.67)	-64.31
Xenetic Biosciences	$3.26 million	1.47	-$2.68 million	($1.16)	-1.80

Gilead Sciences has higher revenue and earnings than Xenetic Biosciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Xenetic Biosciences on 10 of the 14 factors compared between the two stocks.

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.